Welcome to LookChem.com Sign In|Join Free

CAS

  • or

10418-03-8

Post Buying Request

10418-03-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

10418-03-8 Usage

Description

Different sources of media describe the Description of 10418-03-8 differently. You can refer to the following data:
1. Stanozolol is a synthetic anabolic-androgenic steroids (AAS) belonging to the dihydrotestosterone group. It can be used for the treatment of wasting diseases, burn victims, osteroporosis, bone fractures, anemia and even obesity. It can stimulate fat loss without causing reduced lean body mass, inducing hemoglobin production and red blood cell formation. Stanozolol has the following physiological functions: (1) reduction of sex-hormone-binding-globulin; (2) inducing protein synthesis; (3) Maintain nitrogen retention; (4) Increase red blood cells; (5) inhibit glucocorticoids.
2. Stanozolol (Item No. 21167) is an analytical reference standard that is categorized as a synthetic anabolic androgenic steroid. Stanozolol has low urinary excretion; therefore, its metabolites are usually used for detection. Formulations containing stanozolol are used as a treatment for hereditary angioedema. It has also been abused in athletics to improve performance. Stanozolol is regulated as a Schedule III compound in the United States. This product is intended for research and forensic applications.

Chemical Properties

White Solid

Originator

Winstrol,Winthrop,US,1961

Uses

Different sources of media describe the Uses of 10418-03-8 differently. You can refer to the following data:
1. androgen anabolic steroid
2. Anabolic steroid. Androgen. Controlled substance.

Definition

ChEBI: An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been u ed to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes.

Manufacturing Process

To a stirred solution of 1.00 gram of 17β-hydroxy-17α-methyl-4- androsteno[3,2-c]pyrazole in 200 ml of tetrahydrofuran and 400 ml of liquid ammonia was added 2.12 grams of lithium wire during 5 minutes. The dark blue mixture was stirred for 45 minutes. A solution of 40 ml of tertiary-butyl alcohol in 160 ml of diethyl ether was added with stirring.After 15 minutes, 25 ml of ethanol was added with stirring. The mixture turned colorless after several hours, and the liquid ammonia was allowed to evaporate and the mixture was allowed to warm to room temperature over a period of about 15 hours.The solvent was evaporated to yield a colorless solid residue, which was taken up in ethyl acetate-ice water. The two layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, saturated sodium chloride solution and filtered through anhydrous sodium sulfate. The solvent was evaporated to yield 1.20 grams of light tan crystals, MP 151° to 155°C, ultraviolet maximum at 224 mμ (E = 4,095). Two recrystallizations from ethanol afforded: 1st crop, 0.619 grams (62%) of colorless crystals (dried at 120°C in vacuo for 17 hours), MP 232.8° to 238.0°C, ultraviolet maximum at 224 mμ (E = 4,840); 2nd crop, 0.142 gram (14%) of colorless crystals, MP 234° to 242°C.

Brand name

Winstrol (Ovation).

Therapeutic Function

Anabolic

Synthesis

Stanozol, 17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol (29.3.13), is made by reducing the double bond at C4–C5 in methyltestosterone, which has independent interest as an anabolic drug of mestanolone (29.3.11). Mestanolone undergoes formylation with ethylformate in the presence of sodium ethoxide, forming a 2-formyl (oxymethylene) derivative (29.3.12), which upon reaction with hydrazine easily cyclizes to the desired stanazole (29.3.13), which is a pyrazol-condensed steroid system.

Veterinary Drugs and Treatments

Labeled indications for the previously marketed veterinary stanozolol product Winstrol?-V (Winthrop/Upjohn) included “…to improve appetite, promote weight gain, and increase strength and vitality…” in dogs, cats and horses. The manufacturer also stated that: “Anabolic therapy is intended primarily as an adjunct to other specific and supportive therapy, including nutritional therapy.” Like nandrolone, stanozolol has been used to treat anemia of chronic disease. Because stanozolol has been demonstrated to enhance fibrinolysis after parenteral injection, it may be efficacious in the treatment of feline aortic thromboembolism or thrombosis in nephrotic syndrome; however, clinical studies and/or experience are apparently lacking for this indication at present.

References

https://www.steroid.com/Stanozolol.php https://pubchem.ncbi.nlm.nih.gov/compound/stanozolol https://en.wikipedia.org/wiki/Stanozolol

Check Digit Verification of cas no

The CAS Registry Mumber 10418-03-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,4,1 and 8 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 10418-03:
(7*1)+(6*0)+(5*4)+(4*1)+(3*8)+(2*0)+(1*3)=58
58 % 10 = 8
So 10418-03-8 is a valid CAS Registry Number.
InChI:InChI=1/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1

10418-03-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma-Aldrich

  • (S1250000)  Stanozolol  European Pharmacopoeia (EP) Reference Standard

  • 10418-03-8

  • S1250000

  • 1,880.19CNY

  • Detail
  • USP

  • (1620005)  Stanozolol  

  • 10418-03-8

  • 1620005-200MG

  • 5,736.51CNY

  • Detail

10418-03-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name stanozolol

1.2 Other means of identification

Product number -
Other names Tevabolin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:10418-03-8 SDS

10418-03-8Synthetic route

17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one

17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan-3-one

stanozolol
10418-03-8

stanozolol

Conditions
ConditionsYield
With hydrazine
stanozolol
10418-03-8

stanozolol

4-Nitrophenyl chloroformate
7693-46-1

4-Nitrophenyl chloroformate

tanozolol-4-nitrophenyl-carbonate

tanozolol-4-nitrophenyl-carbonate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 3h; pH=8.5;76.85%
stanozolol
10418-03-8

stanozolol

17,17-dimethyl-18-nor-5α-androst-13(14)-eno<3,2-c>pyrazole

17,17-dimethyl-18-nor-5α-androst-13(14)-eno<3,2-c>pyrazole

Conditions
ConditionsYield
With hydrogenchloride for 0.25h; Ambient temperature;66%
stanozolol
10418-03-8

stanozolol

methanesulfonyl chloride
124-63-0

methanesulfonyl chloride

(1S,3aS,3bR,5aS,10aS,10bS,12aS)-8-Methanesulfonyl-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-ol
107000-35-1

(1S,3aS,3bR,5aS,10aS,10bS,12aS)-8-Methanesulfonyl-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-ol

Conditions
ConditionsYield
With pyridine at 0 - 20℃; for 1h;56%
ethyl 5-bromovalerate
14660-52-7

ethyl 5-bromovalerate

stanozolol
10418-03-8

stanozolol

A

ethyl-5-{17β-hydroxy-17α-methylpyrazolo[3′,4′:3,2]-5α-androstan-1′-yl}pentanoate

ethyl-5-{17β-hydroxy-17α-methylpyrazolo[3′,4′:3,2]-5α-androstan-1′-yl}pentanoate

B

ethyl 5-{17α-methyl-17β-hydroxypyrazolo[4′,5′:2,3]-5α-androstan-1′-yl}pentanoate

ethyl 5-{17α-methyl-17β-hydroxypyrazolo[4′,5′:2,3]-5α-androstan-1′-yl}pentanoate

Conditions
ConditionsYield
With caesium carbonate In N,N-dimethyl-formamide at 80℃; for 5h; Microwave irradiation;A 38%
B 28%
stanozolol
10418-03-8

stanozolol

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester
21085-72-3

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester

A

2′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

2′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

B

1′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

1′‑[N‑(methyl 2,3,4‑tri‑O‑acetyl‑1‑deoxy‑β‑d‑glucuronosyluronate)]‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑17β‑ol

Conditions
ConditionsYield
With mercury(II) cyanide; mercury dibromide In nitromethane; benzene for 3h;A 17%
B 5%
pyridine
110-86-1

pyridine

stanozolol
10418-03-8

stanozolol

stanozolol 17β-sulfate pyridinium salt

stanozolol 17β-sulfate pyridinium salt

Conditions
ConditionsYield
With chlorosulfonic acid 1.) -5 deg C, 2.) RT, 3 h; Yield given. Multistep reaction;
stanozolol
10418-03-8

stanozolol

Sulfuric acid mono-((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl) ester

Sulfuric acid mono-((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-7,8-diaza-dicyclopenta[a,h]phenanthren-1-yl) ester

Conditions
ConditionsYield
With sulfur trioxide pyridine complex In N,N-dimethyl-formamide for 2h; Ambient temperature;
stanozolol
10418-03-8

stanozolol

17-epistanozolol
145841-85-6, 125636-91-1

17-epistanozolol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sulfur trioxide pyridine complex / dimethylformamide / 2 h / Ambient temperature
2: K2CO3 / dimethylformamide; H2O / 72 h
View Scheme
L-malic acid
2174-58-5

L-malic acid

stanozolol
10418-03-8

stanozolol

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*(S-methylsuccinic acid)

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*(S-methylsuccinic acid)

Conditions
ConditionsYield
In methanol Milling;
2-(R)-methylsuccinic acid
3641-51-8

2-(R)-methylsuccinic acid

stanozolol
10418-03-8

stanozolol

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*2(R-methylsuccinic acid)

((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f ]indazol-1-ol)*2(R-methylsuccinic acid)

Conditions
ConditionsYield
In methanol Milling;
stanozolol
10418-03-8

stanozolol

C21H30N2O

C21H30N2O

Conditions
ConditionsYield
With titanium(IV) oxide In water; acetonitrile Reagent/catalyst; UV-irradiation;
stanozolol
10418-03-8

stanozolol

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑1′‑yl)‑β‑d‑glucopyranuronic acid

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑1′‑yl)‑β‑d‑glucopyranuronic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h
2.1: lithium hydroxide monohydrate / methanol; water / 7 h / 20 °C
2.2: amberlite 120 ion resin / 0.25 h
View Scheme
stanozolol
10418-03-8

stanozolol

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑2′‑yl)‑β‑d‑glucopyranuronic acid

1‑deoxy‑1‑(17β‑hydroxy‑17α‑methyl‑5α‑androstano[3,2‑c]pyrazol‑2′‑yl)‑β‑d‑glucopyranuronic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: mercury(II) cyanide; mercury dibromide / nitromethane; benzene / 3 h
2.1: lithium hydroxide monohydrate / methanol; water / 6 h / 20 °C
2.2: amberlite 120 ion resin / 0.25 h
View Scheme
stanozolol
10418-03-8

stanozolol

C44H72N6O7S

C44H72N6O7S

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
stanozolol
10418-03-8

stanozolol

C43H68N6O8S

C43H68N6O8S

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation
4: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
stanozolol
10418-03-8

stanozolol

C30H43N3O5

C30H43N3O5

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: dicyclohexyl-carbodiimide / N,N-dimethyl-formamide / 20 °C
View Scheme
stanozolol
10418-03-8

stanozolol

C26H40N2O3

C26H40N2O3

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
View Scheme
stanozolol
10418-03-8

stanozolol

C26H40N2O3

C26H40N2O3

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
View Scheme
stanozolol
10418-03-8

stanozolol

17α-methyl pyrazolo[3′,4′:3,2]-5α-androstane-17β-yl-hemisuccinate

17α-methyl pyrazolo[3′,4′:3,2]-5α-androstane-17β-yl-hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 100 °C / Microwave irradiation
View Scheme
stanozolol
10418-03-8

stanozolol

C44H72N6O7S

C44H72N6O7S

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: caesium carbonate / N,N-dimethyl-formamide / 5 h / 80 °C / Microwave irradiation
2: sodium hydroxide; methanol / water / 1.5 h / 20 °C
3: benzotriazol-1-ol; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 5 h / 20 °C / Inert atmosphere
View Scheme
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

stanozolol
10418-03-8

stanozolol

A

Boc-stanozolol

Boc-stanozolol

B

C26H40N2O3

C26H40N2O3

Conditions
ConditionsYield
With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃;
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

stanozolol
10418-03-8

stanozolol

C35H56N2O6Si

C35H56N2O6Si

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydrogencarbonate / water; tetrahydrofuran / 20 °C
2: dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / chloroform / 20 °C
View Scheme
stanozolol
10418-03-8

stanozolol

C26H38N2O4

C26H38N2O4

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dmap / dichloromethane / 72 h
2: sodium hydroxide / methanol / 1 h / 20 °C
View Scheme
stanozolol
10418-03-8

stanozolol

succinic acid monomethylester chloride
1490-25-1

succinic acid monomethylester chloride

A

C26H38N2O4

C26H38N2O4

B

C26H38N2O4

C26H38N2O4

Conditions
ConditionsYield
With dmap In dichloromethane for 2h;
stanozolol
10418-03-8

stanozolol

succinic acid monomethylester chloride
1490-25-1

succinic acid monomethylester chloride

A

C31H44N2O7

C31H44N2O7

B

C31H44N2O7

C31H44N2O7

Conditions
ConditionsYield
With dmap In dichloromethane for 72h; Overall yield = 90 percent;

10418-03-8Upstream product

10418-03-8Downstream Products

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 10418-03-8